Verily’s Study Watch [Image courtesy of Verily]
Verily — a life science company under Alphabet (NSDQ:GOOGL) — recently received an FDA 510(k) clearance to include an irregular pulse monitor in its Study Watch wearable.
“We’ve worked carefully to meet the FDA’s stringent requirements for medical devices, and with this new indication, will explore opportunities to leverage Study Watch as a measure of irregular pulse in clinical settings across our cardiovascular programs, including our collaboration with iRhythm,” Dr. William Marks, head of clinical science at Verily, said in a blog post yesterday.
